Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. reported a net loss of $90.6 million for fiscal year 2025, driven by total operating expenses of $93.3 million, primarily consisting of research and development costs of $68.6 million and general and administrative expenses of $24.7 million. The company generated $2.7 million in other income, mainly from interest income, partially offsetting the operating loss. Cash flow from operations was negative $68.3 million, but the company raised $108.4 million from financing activities, including $106.0 million from equity issuance, resulting in a net cash increase of $96.2 million. The balance sheet shows total assets of $146.9 million, with $100.5 million in cash and cash equivalents and $57.1 million in short-term marketable securities, providing liquidity for continued operations. The company's accumulated deficit increased to $605.0 million, reflecting ongoing investment in research and development activities.

Key Takeaways